Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GCK | P35557 | 7/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5219604 | 0.87 | GCK (0.52) | GCKKCNH2 | |
| SCHEMBL13343240 | 0.80 | GCK (0.61) | GCKKCNH2 | |
| SCHEMBL990120 | 0.74 | GCK (0.43) | GCKMEN1KMT2ALMNAPTGES | |
| SCHEMBL2653455 | 0.74 | AR (0.41) | TSHRGCKKCNH2MAPTAR | |
| SCHEMBL2654537 | 0.71 | KDM4E (0.43) | TSHRGCKLMNAKCNH2MAPT | |
| SCHEMBL5219286 | 0.70 | MAOB (0.42) | TSHRMEN1KMT2ALMNAMAPT | |
| SCHEMBL5222914 | 0.70 | NOX1 (0.42) | TSHRGCKMEN1KMT2AKCNH2 | |
| SCHEMBL2657438 | 0.70 | GCK (0.64) | GCKLMNAPTGESALOX5MAPT | |
| SCHEMBL2653764 | 0.67 | LMNA (0.53) | MEN1KMT2ALMNAMAPT | |
| SCHEMBL23628951 | 0.64 | MRGPRX1 (0.46) | TSHRLMNAKCNH2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709505-B2 | Benzofuran derivatives, process for their preparation and intermediates thereof | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-1578745-B1 | BENZOFURAN DERIVATivES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | ASTRAZENECA AB (SE) | 2007-11-14 | — | — | EP | disclosed |
| US-20060058353-A1 | Benzofuran derivatives, process for their preparation and intermediates thereof | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1578745-A1 | BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | Astrazeneca AB (SE) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004046139-A1 | BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058353-A1 | Benzofuran derivatives, process for their preparation and intermediates thereof | GCK, PDK2, GCKR | TSHR 1843/4885GCK 1/4885MEN1 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.